Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **host-microbiome interface** is the anatomical and functional boundary where a host organism (such as human epithelial or mucosal surfaces) interacts with its resident microbial community (microbiota)[1][3][6]. This interface includes physical structures (e.g., gut mucosa), secreted compounds, and cellular and molecular signals coordinating immune tolerance, defense, metabolism, and homeostasis. The interface is dynamic, with mutual influences between host and microbes shaping health outcomes and responses to disease. Disruption of homeostasis at this interface (dysbiosis) is implicated in a wide range of diseases, including inflammatory, metabolic, and infectious conditions. Therapeutic manipulation of the host-microbiome interface (using probiotics, prebiotics, or fecal transplants) aims to restore or optimize these interactions[2][6][7].
Modulation of microbial composition Restoration or alteration of barrier function Immune modulation Alteration of local or systemic metabolites
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host-microbiome interface.